Literature DB >> 23089896

ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.

Naoto Hashimoto1, Noritaka Nakamichi, Shinya Uwafuji, Kohei Yoshida, Tomoko Sugiura, Akira Tsuji, Yukio Kato.   

Abstract

The role of two ATP binding cassette transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), in transdermal absorption of a typical common substrate was examined in vivo. Skin and plasma concentrations of rhodamine123 (Rho123) after dermal application were reduced in P-gp knockout (mdr1a/1b⁻/⁻) mice and were below the detection limit in P-gp and BCRP triple-knockout (mdr1a/1b/bcrp⁻/⁻) mice. Lower epidermal-to-hypodermal permeation of Rho123 in mdr1a/1b/bcrp⁻/⁻ mouse skin compared to the wild-type mouse skin was confirmed in an Ussing-type chamber experiment. The reduction in skin concentration after dermal application in mdr1a/1b/bcrp⁻/⁻ mice was greater in the dermis than in the epidermis, suggesting functional expressions of these transporters in two distinct skin compartments. Coadministration of the inhibitor itraconazole reduced the skin and plasma concentrations of Rho123 in the wild-type mice, but not in mdr1a/1b/bcrp⁻/⁻ mice, and a marked decrease of Rho123 concentration was seen in the dermis, demonstrating that the functional activities of these transporters can be modulated in vivo. On the other hand, the distribution of Rho123 after intravenous infusion was higher in mdr1a/1b/bcrp⁻/⁻ mice than in the wild-type mice. This supports the occurrence of vectorial transport from the skin into systemic circulation, and is consistent with the immunohistochemical localization of P-gp and BCRP in mouse dermal endothelial cells. BCRP was immunohistochemically identified in human epidermis and dermal endothelial cells. Thus, our findings show that ABC transporters in different compartments of the skin contribute to transdermal absorption of a typical substrate in vivo and can be modulated by a specific inhibitor. These findings have implications for transdermal drug delivery. Crown
Copyright © 2012. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089896     DOI: 10.1016/j.jconrel.2012.10.011

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Scrolls: novel microparticulate systems for enhanced delivery to/across the skin.

Authors:  Irit Allon; Elka Touitou
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

2.  Topical Application of a Dual ABC Transporter Substrate and NF-κB Inhibitor Blocks Multiple Sources of Cutaneous Inflammation in Mouse Skin.

Authors:  Luowei Li; Christophe Cataisson; Brittany Flowers; Elise Fraser; Vanesa Sanchez; Chi-Ping Day; Stuart H Yuspa
Journal:  J Invest Dermatol       Date:  2019-01-23       Impact factor: 8.551

3.  Optimization of Storage Temperature for Retention of Undifferentiated Cell Character of Cultured Human Epidermal Cell Sheets.

Authors:  Catherine J Jackson; Sjur Reppe; Jon R Eidet; Lars Eide; Kim A Tønseth; Linda H Bergersen; Darlene A Dartt; May Griffith; Tor P Utheim
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 4.  Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives.

Authors:  Laure-Alix Clerbaux; Alicia Paini; Annie Lumen; Hanan Osman-Ponchet; Andrew P Worth; Olivier Fardel
Journal:  Environ Int       Date:  2019-03-08       Impact factor: 9.621

5.  Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.

Authors:  Kazumi Sano; Kazuhiko Nakadate; Kazuhiko Hanada
Journal:  BMC Cancer       Date:  2020-04-06       Impact factor: 4.430

Review 6.  ABCB1 in dermatology: roles in skin diseases and their treatment.

Authors:  H J Weng; T F Tsai
Journal:  J Mol Med (Berl)       Date:  2021-08-09       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.